Literature DB >> 16203774

High frequency of hereditary colorectal cancer in Newfoundland likely involves novel susceptibility genes.

Michael O Woods1, Angela J Hyde, Fiona K Curtis, Susan Stuckless, Jane S Green, Aaron F Pollett, J Desmond Robb, Roger C Green, Marina E Croitoru, Amanda Careen, Jason A W Chaulk, Jegan Jegathesan, John R McLaughlin, Steven S Gallinger, H Banfield Younghusband, Bharati V Bapat, Patrick S Parfrey.   

Abstract

PURPOSE: Newfoundland has one of the highest rates of colorectal cancer in North America. The most common hereditary form of colorectal cancer is hereditary nonpolyposis colorectal cancer caused by mutations in genes involved in mismatch repair. Our purpose was to determine the proportion of hereditary colorectal cancer and to determine the genetic basis of disease in both population and clinically referred cohorts from Newfoundland. EXPERIMENTAL
DESIGN: Seventy-eight colorectal cancer patients were accrued over a 2-year period from the Avalon Peninsula of Newfoundland. We also examined 31 hereditary nonpolyposis colorectal cancer-like families, which had been referred to the Provincial Medical Genetics Program. Tumors from probands were tested by immunohistochemistry for deficiencies in MLH1, MSH2, and MSH6 proteins and tested for DNA microsatellite instability. Mutation analyses of MLH1, MSH2, and MSH6 were undertaken by direct sequencing and an assay to detect deletions, amplifications, and rearrangements in MSH2 and MLH1.
RESULTS: We identified eight population-based families that fulfill the Amsterdam I or II criteria, 4 (50%) of which seem to have hereditary cancer not attributable to the most commonly mutated mismatch repair genes. In addition, in 16 of 21 (76%) referred families fulfilling Amsterdam I or II criteria, no mutations were found in the three most commonly altered mismatch repair genes, and tumor analyses corroborated these findings.
CONCLUSIONS: It seems that strong and novel genetic causes of hereditary colorectal cancer are responsible for a high proportion of colorectal cancer in this population. Conditions are suitable for the identification of these genes by linkage studies of large Newfoundland cancer families.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203774     DOI: 10.1158/1078-0432.CCR-05-0726

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Public attitudes towards genomic risk profiling as a component of routine population screening.

Authors:  S G Nicholls; B J Wilson; S M Craigie; H Etchegary; D Castle; J C Carroll; B K Potter; L Lemyre; J Little
Journal:  Genome       Date:  2013-08-31       Impact factor: 2.166

2.  Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment.

Authors:  Laura Belvederesi; Francesca Bianchi; Cristian Loretelli; Raffaella Bracci; Stefano Cascinu; Riccardo Cellerino
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

3.  The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease.

Authors:  M O Woods; H B Younghusband; P S Parfrey; S Gallinger; J McLaughlin; E Dicks; S Stuckless; A Pollett; B Bapat; M Mrkonjic; A de la Chapelle; M Clendenning; S N Thibodeau; M Simms; A Dohey; P Williams; D Robb; C Searle; J S Green; R C Green
Journal:  Gut       Date:  2010-08-03       Impact factor: 23.059

4.  A novel and rapid method of determining the effect of unclassified MLH1 genetic variants on differential allelic expression.

Authors:  Sheron Perera; Brian Li; Soultana Tsitsikotas; Lily Ramyar; Aaron Pollett; Kara Semotiuk; Bharati Bapat
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

5.  Mismatch repair deficiency screening via immunohistochemical staining in young Asians with colorectal cancers.

Authors:  Min-Hoe Chew; Poh-Koon Koh; Melinda Tan; Kiat-Hon Lim; Loi Carol; Choong-Leong Tang
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

6.  Efficacy of an educational intervention on family physicians' risk assessment and management of colorectal cancer.

Authors:  J C Carroll; S Blaine; J Permaul; E Dicks; E Warner; M J Esplen; H Rothenmund; K Semotiuk; G Worrall; J McLaughlin
Journal:  J Community Genet       Date:  2014-04-09

7.  Very high incidence of familial colorectal cancer in Newfoundland: a comparison with Ontario and 13 other population-based studies.

Authors:  R C Green; J S Green; S K Buehler; J D Robb; D Daftary; S Gallinger; J R McLaughlin; P S Parfrey; H B Younghusband
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

8.  Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer.

Authors:  Miralem Mrkonjic; Nicole M Roslin; Celia M Greenwood; Stavroula Raptis; Aaron Pollett; Peter W Laird; Vaijayanti V Pethe; Theodore Chiang; Darshana Daftary; Elizabeth Dicks; Stephen N Thibodeau; Steven Gallinger; Patrick S Parfrey; H Banfield Younghusband; John D Potter; Thomas J Hudson; John R McLaughlin; Roger C Green; Brent W Zanke; Polly A Newcomb; Andrew D Paterson; Bharati Bapat
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

9.  Profound, prelingual nonsyndromic deafness maps to chromosome 10q21 and is caused by a novel missense mutation in the Usher syndrome type IF gene PCDH15.

Authors:  Lance Doucette; Nancy D Merner; Sandra Cooke; Elizabeth Ives; Dante Galutira; Vanessa Walsh; Tom Walsh; Linda MacLaren; Tracey Cater; Bridget Fernandez; Jane S Green; Edward R Wilcox; Lawrence I Shotland; Larry Shotland; Xiaoyan Cindy Li; X C Li; Ming Lee; Mary-Claire King; Terry-Lynn Young
Journal:  Eur J Hum Genet       Date:  2008-12-24       Impact factor: 4.246

10.  Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario.

Authors:  Yun-Hee Choi; Michelle Cotterchio; Gail McKeown-Eyssen; Monga Neerav; Bharati Bapat; Kevin Boyd; Steven Gallinger; John McLaughlin; Melyssa Aronson; Laurent Briollais
Journal:  Hered Cancer Clin Pract       Date:  2009-08-23       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.